Xenon Pharmaceuticals Inc. (XENE)
After hours:
| Previous close | 38.34 |
| Open | 38.14 |
| Bid | 38.11 x 1100 |
| Ask | 40.45 x 900 |
| Day's range | 38.14 - 39.43 |
| 52-week range | 24.94 - 41.39 |
| Volume | |
| Avg. volume | 387,375 |
| Market cap | 2.451B |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.56 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.67 |
- Simply Wall St.
Investors in Xenon Pharmaceuticals (NASDAQ:XENE) have made a fantastic return of 965% over the past five years
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well...
- GlobeNewswire
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101 Phase 3 program development and cash runway into 2026 BURNABY, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined recent progress in its clinical programs and key milestones for 2023. Mr. Ian Mortimer,
- GlobeNewswire
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 9-12, 2023. Company Presentation Details: Date:Monday, January 9, 2023 Time:7:30 am Pacific Time (10:30 am Eastern Time) Presenters:Ian Mortimer, President and CEO A live webcast of the company presentati
